Incorrect Treatment Group in Results and Error in Legend of Figure 2

In the article titled "Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial," a single instance of the incorrect treatment group was named in the beginning of the Results, and the overall survival rates for nivolumab and dacarbazine in the caption for part A of Figure 2 were incorrect. In the Results, the sentence has been revised to read, "…in the dacarbazine group, the median age of patients was 66 years (25-87 years)…", and in the caption for part A of Figure 2, the rates have been revised to read, "For nivolumab, the overall survival rate at 1 year was 71%; 2 years, 58%; and 3 years, 51%. For dacarbazine, the overall survival rate at 1 year was 46%; 2 years, 26%; and 3 years, 22%." This article has been corrected online.

https://ift.tt/2BfpeTS